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Background: The reasons for the worldwide sex disparity in the incidence of hepatocellular carcinoma (HCC)
remain elusive. We investigated the role of multiple pregnancies on the associations between viral hepatitis C (HCV)
infection and HCC risk among Egyptian women.
Methods: We used data collected from blood specimens and questionnaires administered to female HCC cases
and controls in Cairo, Egypt, from 1999 through 2009. HCV infection was defined as being sero-positive for either
anti-HCV antibodies or HCV-RNA. Using logistic regression models we calculated odds ratios (OR) and 95% confidence
intervals (CI) to estimate the associations between being HCV positive and HCC risk, and how it is modified by the
number of pregnancies, after adjustment for other factors, including hepatitis B status.
Results: Among 132 confirmed female cases and 669 controls, the risk of HCV-related HCC increased with the number
of pregnancies. Women infected with HCV had higher risk for HCC if they had more than five pregnancies, as
compared to those who had five or fewer pregnancies (adjusted OR (95% CI): 2.33 (1.29-4.22)). The association of
HCV infection with HCC risk was significantly greater among the former (21.42 (10.43-44.00)) than among the latter
(6.57 (3.04-14.25)).
Conclusion: Having multiple pregnancies increases the risk of HCV-related HCC among Egyptian women, raising
questions about the roles of estrogens and other pregnancy-related hormones in modulating HCV infection and
its progression to HCC.
Keywords: Hepatocellular carcinoma, Hepatitis C, Epidemiology, Pregnancy, Women’s healthBackground
Hepatocellular carcinoma (HCC) is increasing worldwide
and particularly in Egypt [1,2] where the prevalence of
hepatitis C viral (HCV) infection, a well-established HCC
risk factor [3,4], is the highest in the world [5]. Chronic
infection with hepatitis C can lead to liver inflammation,
cirrhosis, and ultimately to hepatocarcinogenesis [6,7].
Also known is that HCC disproportionately strikes more
men than women, worldwide [1,8]. In searching for the
mechanisms underlying gender difference in cancer
incidence, investigators have examined risk factors before
and after menopause, role of steroid hormones and specif-
ically estrogens, with the assumption that the latter has a
potential protective role [9-14]. Some investigators docu-
mented increased risk of HCC with increased exposure to* Correspondence: samr@epi.umaryland.edu
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unless otherwise stated.estrogen and/or increased duration of higher estrogen
levels [12,13], and others found an inverse association
[9,10,14]. Associations between parity and liver cancer risk
among women were also investigated. Among Taiwanese
women, Fwu et al. found that the higher the parity was
the lower was the incidence of HCC [15]; whereas Chen
et al. reported a standardized mortality rate (SMR) of 1.18
(95% CI: 1.06–1.30) for liver cancer among Taiwanese
women with at least five children as compared to those in
general population [16]. When multiparous (≥ 4 children)
Italian women were compared to nulliparous, the relative
risk for liver cancer was found to be 3.3 [17]. Therefore, to
date, the studies of liver cancer risk and reproductive hor-
mones (estrogen and others present during pregnancy)
have yielded conflicting results.
Using data from our case–control study of HCC in
Egypt [18], we investigated the role of multiple pregnancies
in the association between HCV infection and HCC risk.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
Detailed methods of recruitment, case confirmation,
consent, and interview for the parent study were previ-
ously published [18]. Briefly, consecutive patients with
presumed diagnosis of HCC were recruited from the
National Cancer Institute of Cairo University from 1999
through 2009. They were included in the study only if
their liver malignancy was confirmed as primary by either
1) pathology or cytology evidence, 2) alpha-fetoprotein
(AFP) levels > 1000 ng/ml, or 3) AFP levels > 300 ng/ml
along with evidence of single liver mass from an ultrasound
or CT scan. All other cases, including non-malignant liver
tumors or metastatic lesions, were excluded. Controls were
recruited from the Orthopedic Department of the nearby
Kasr El Aini Medical Center of Cairo University, which
receives patients from the same geographical areas as
the cases. They were frequency-matched to cases by
rural versus urban birthplace, gender, and 5-year age
category. The institutional review boards at the National
Cancer Institute of Cairo University, Kasr El Aini Faculty
of Medicine, and Georgetown University approved the
study protocol [18].
Questionnaire and biological specimen
For the parent study, each participant granted consent
via either written or witnessed oral agreement. The
30 minute Arabic-language questionnaire was pilot tested
before being administered by trained research assistants in
face-to-face interviews; in addition to questions pertaining
to socio-demographic characteristics that included age,
education level and place of birth, environmental expo-
sures, and medical histories, women were asked about
number of pregnancies and live born children. A speci-
men of whole blood was collected from each participant
and tested for serological markers of HBV and HCV, as
described below [18].
Laboratory assays
The HCV antibody was measured using an enzyme-linked
immunosorbant assay (ELISA) from Abbott Laboratories
(Wiesbaden, Germany). For HCV RNA determination,
a reverse transcription-polymerase chain reaction was
completed according to the method of Abdel Hamid
et al., using nested primers from the highly conserved
5′-untranslated region (5′-UTR) of the HCV genome
[19]. HBV core antibody (HBcAb) was determined
using the CORZYME competitive immunoassay (Abbott
Laboratories, Wiesbaden, Germany), while HBV surface
antigen (HBsAg) was assayed using the enzyme immuno-
assay Auszyme method (Abbott Laboratories, Wiesbaden,
Germany). Any participant was considered HCV infected
if she tested positive for either HCV RNA or anti-HCV
antibodies; similarly, detection of anti-HBV surface antigenor anti-HBV core antibodies was considered as HBV
infection.
Statistical analysis
HCV infection, the main predictor, was used as dichotom-
ous variable, and the number of pregnancies was used as a
continuous variable, but also as dichotomous based on the
median in the controls. Age was used as continuous but
also was grouped in three categories (≤ 45, < 45 to ≤ 55,
and >55) for further descriptive analyses. Logistic regres-
sion models were used to calculate the odds ratio (OR)
and 95% confidence interval (CI) to estimate the strength
of the association between independent variables and
HCC. Independent variables, including pregnancy number
(continuous or categorical) were tested for their potential
interactions with HCV infection. All models were adjusted
for age, urban vs. rural birthplace, education (none versus
some) and serological markers of HBV. All statistical ana-
lyses were performed using SAS, version 9.3.
Results
A total of 132 female HCC cases and 669 controls par-
ticipated in this study (with participation rates of 95%
and 80%, respectively). Table 1 shows the characteristics
of the cases and controls. Controls were significantly
younger than cases and more likely to be born in urban
areas. Approximately 50% of the controls and 70% of the
cases were illiterate. A greater proportion of cases than
controls reported more than five pregnancies and live
births. The median number of pregnancies for cases and
controls were 7 and 5, respectively. This difference be-
tween cases and controls was consistently noted in the
agegroups (6 and 4 for the ≤ 45 y old group; 7 and 6 for
the < 45 to ≤ 55 group; and 8 and 7 for those >55). Cases
were more likely (81.1%) than controls (19.3%) to be HCV
positive.
HCV infection was significantly associated with HCC
(OR (95% CI): 13.50 (8.09-22.53) after adjustment for
age, birthplace, education, and HBV infection (Table 2,
model 1). Assessed separately, the number of pregnan-
cies was positively associated with HCC risk after adjust-
ment for the same covariates, whether we used the variable
as continuous (1.08 (1.02-1.16), or as dichotomous (≤ 5
versus > 5 pregnancies based on the median among
controls) (1.84 (1.17-2.89), Table 2, model 2). When
both variables, HCV infection and number of pregnancy
(dichotomous), and an interaction term (HCV infection*-
pregnancy number) were included with the adjustment
covariates in the regression model (Table 2, model 3), we
found the interaction term to be significant (p = 0.02).
Table 2 , model 3, illustrates the adjusted ORs and 95% CI
of having HCC for the different strata; in the presence
of HCV infection, the risk of having HCC was greater
among women who had more than five pregnancies
Table 1 Characteristics and Infectious hepatitis statuses
of women participants in the case–control study of
hepatocellular carcinoma in Egypt
Controls N = 669 Cases N = 132 p-value
Age, mean (SD) 45.4 (14.9) 52.2 (10.5) <0.0001
Age group N (%)
≤ 45 332 (49.6) 32 (24.3)
45 < to ≤55 165 (24.7) 46 (34.8) <0.0001
> 55 172 (25.7 54 (40.9)
Birthplace N (%)
Urban 224 (33.6) 22 (16.8)
Rural 443 (66.4) 109 (83.2) 0.0001
missing 2 1
Education N (%)
None 333 (49.8) 92 (69.7)
Some 336 (50.2) 40 (30.3) <0.0001
HCV infection N (%)
No 540 (80.7) 25 (18.9)
Yes 129 (19.3) 107 (81.1) <0.0001
HBV infection, N (%)
No 479 (71.6) 47 (35.6)
Yes 190 (28.4) 85 (64.4) <0.0001
Number of pregnancies,
Mean ± SD 5.6 ± 3.3 7.3 ± 3.4 <0.0001
Median 5 7
Categories, N (%)
0- 5 374 (55.9) 39 (29.5)
> 5 295 (44.1) 93 (70.4) <0.0001
Number of children,
Mean ± SD 4.7 ± 2.6 6.3 ± 2.7 <0.0001
Median 5 6
Categories, N (%)
0- 5 456 (68.2) 54 (40.9)
> 5 213 (31.8) 78 (59.1) <0.0001
Table 2 Multivariable regression analyses of the
association between hepatitis C viral infection (HCV),
pregnancy number and hepatocellular carcinoma among
Egyptian women







≤ 5 pregnancies Reference
> 5 pregnancies 1.84 (1.17-2.89)
Model 3




HCV infection among women
with > 5 pregnancies
No Reference
Yes 21.42 (10.43-44.00)
Pregnancy number among women
without HCV infection
≤ 5 pregnancies Reference
> 5 pregnancies 0.72 (0.30-1.73)
Pregnancy number among women
with HCV infection
≤ 5 pregnancies Reference




*Adjusted odds ratio (95% confidence interval); All models were adjusted for
age, birthplace, education, and HBV infection.
Model 1 included HCV infection as the main variable with the
adjustment covariates.
Model 2 included dichotomized pregnancy number (≤ 5 versus > 5) as the
main variable with the adjustment covariates.
Model 3 included both HCV infection and dichotomized pregnancy number,
and the interaction term dichotomized Pregnancy number*HCV interaction, in
addition to the adjustment covariates.
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fewer ((6.57 (3.04-14.25)). And among those infected
with HCV, having more than five pregnancies increased
the odds of developing HCC (2.33 (1.29-4.22)) as com-
pared to those with five or fewer pregnancies. In the ab-
sence of HCV, pregnancy number was not associated with
HCC risk.
Discussion
Among Egyptian women in this case–control study, we
found that multiple pregnancies increased the HCV-
related risk for HCC. Although several previous studies
have shown increased risk with estrogen exposure, this is
the first observation addressing the interaction betweenpregnancy and HCV infection and its subsequent impact
on HCC risk.
In searching for an explanation to the consistent
higher incidence of HCC in men as compared to women,
investigators postulated a role for estrogens and its pro-
tective effects; to date, the results have been inconsistent;
some found increased risk of HCC with increased expos-
ure to estrogen and/or increased duration of higher estro-
gen levels [12,13], while others documented an inverse
association [9,10,14,15]. Estrogen was reported to inhibit
the secretion of inflammatory interleukin from hepatic
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to have a protective effect on hepatic cells [9]. Our data
showing that multiple pregnancies, with their recurrent
high levels of circulating estrogens, increased HCC risk
among HCV infected women do not support this hypoth-
esis. On the other hand, exacerbation of chronic hepatitis
C after delivery was reported among pregnant women
carrying the viruses [20]. One of the explanations for this
flare up is the effective rebound of the immune system,
which is known to be suppressed during pregnancy
[21,22] most likely by the placental secretion of human
chorionic gonadotropin (hCG) [23]; and after delivery,
there is reactivation of the inflammatory cell response
[20,24,25]. Multiple pregnancies, and thus multiple deliv-
eries, can lead to multiple flaring episodes of the clinical
signs of chronic hepatitis C, which, in turn, can lead to
liver cirrhosis and carcinogenesis among women; a con-
cept that is supported by our present results. Complex
interactions between gender, serum interleukin levels,
estradiol level, and HCC risk have also been reported
[11]. In addition, Increased risk of liver cancer with in-
creased parity have been previously reported in different
populations [16,17]; and so were progesterone and hCG
as immunosuppressors during pregnancy [21].
Our study population was large enough to investigate
women’s HCC associations with HCV infection and
pregnancy number after adjustment for HBV. In addition,
hepatocellular carcinoma diagnosis was confirmed by strin-
gent criteria. At the same time, some limitations should be
considered. The present analysis used a dataset established
for a different original aim, and therefore we lacked some
additional and potentially relevant variables, such as age at
menarche, age at menopause, and age at first pregnancy.
Future studies should also consider the use of oral contra-
ceptives and hormone replacement therapy by women
(neither of which were queried in our survey).Conclusion
The present study provides evidence for frequent pregnan-
cies, and thus possibly hormonal factors during pregnancy
or after delivery, as modulators of the HCV-related risk
for HCC among Egyptian women. Future studies should
consider 1) tracking the levels of Alanine Transaminase
(ALT) (marker of liver injury) following delivery, and 2)
assessing the relationship between multiple pregnancies
and cirrhotic stages, in women with HCV infection.
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